Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis
Tóm tắt
Anti-TNF agents like infliximab, etanercept and adalimumab are efficacious in the treatment of ankylosing spondylitis (AS), psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Lack of efficacy, side effects and loss of efficacy over time may be reasons for switching to a second anti-TNF agent and sometimes switching to a third anti-TNF agent may be useful. Effects of switching may be different in patients with AS, PsA and RA. We analysed data of 301 patients with rheumatic diseases treated with anti-TNF agents. Forty-six patients had AS, 63 PsA and 192 RA. Totally 38% of these patients received more than one anti-TNF agent. Switching to a second anti-TNF agent was necessary in 115 (38%) of our patients, in detail in 11 of our AS patients, in 21 of PsA patients and in 83 of RA patients. Patient with PsA showed the best response rate to the second anti-TNF agent. Finally, 46 patients, 5 with SPA, 3 with PsA and 38 with RA received a third anti-TNF agent. We conclude that anti-TNF switching in AS and PsA is less frequent than in RA patients. Survival of anti-TNF agents in AS (p = 0.025) and also in PsA (n.s., p = 0.215) seems to be better than in RA. Switching anti-TNF agents for loss of efficacy over time may have the best effect in patients with AS, PsA and predominantly in RA. Our data suggest that switching for lack of efficacy in RA patients cannot be recommended, but may be an alternative in patients with AS and PsA. Switching to a second anti-TNF agent for side effects may be reasonable, switching to a third anti-TNF agent again for side effects cannot be recommended.
Tài liệu tham khảo
citation_journal_title=Clin Exp Rheumatol; citation_title=Switching between biological agents; citation_author=RF van Vollenhoven; citation_volume=22; citation_issue=Suppl 1; citation_publication_date=2004; citation_pages=S115-S121; citation_id=CR1
citation_journal_title=Arthritis Res Ther; citation_title=Switching TNFα antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period; citation_author=JJ Gomez-Reino, L Carmona; citation_volume=8; citation_publication_date=2006; citation_pages=R29; citation_doi=10.1186/ar1881; citation_id=CR2
citation_journal_title=Acta Reumatol Port; citation_title=How good is to switch between biologics? A systematic review of the literature; citation_author=L Carmona, A Ortiz, MA Abad; citation_volume=32; citation_publication_date=2007; citation_pages=113-128; citation_id=CR3
citation_journal_title=Klinik; citation_title=Biologika – Verordnungsmodalitäten und "Switching" in der Rheumatologie; citation_author=G Haberhauer, P Fasching; citation_volume=1; citation_publication_date=2009; citation_pages=59-61; citation_id=CR4
citation_journal_title=Universum Inn Med; citation_title=TNF-α-Blockertherapie in der Rheumatologie – Effektivität des Substanzwechsels bei Therapieversagen und bei Nebenwirkungen; citation_author=G Haberhauer, J Feyertag, P Fasching; citation_volume=5; citation_publication_date=2009; citation_pages=83-85; citation_id=CR5
citation_journal_title=J Rheumatol; citation_title=Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data; citation_author=C Delaunay, V Farrenq, A Marini-Portugal; citation_volume=32; citation_publication_date=2005; citation_pages=2183-2185; citation_id=CR6
citation_journal_title=Arthr Res Ther; citation_title=Survival of TNFα antagonists in spondyloarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER; citation_author=L Carmona, JJ Gomez-Reino; citation_volume=8; citation_publication_date=2006; citation_pages=R72; citation_doi=10.1186/ar1941; citation_id=CR7
citation_journal_title=Ann Rheum Dis; citation_title=Switching tumor necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period; citation_author=F Conti, F Ceccarelli, E Marocchi; citation_volume=66; citation_publication_date=2007; citation_pages=1393-1397; citation_doi=10.1136/ard.2007.073569; citation_id=CR8
citation_journal_title=Joint Bone Spine; citation_title=Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update; citation_author=T Pham, B Fautrel, E Dernis; citation_volume=74; citation_publication_date=2007; citation_pages=638-646; citation_doi=10.1016/j.jbspin.2007.10.003; citation_id=CR9
citation_journal_title=Ann Rheum Dis; citation_title=Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience; citation_author=LC Coates, LS Cawkwell, NW Ng; citation_volume=67; citation_publication_date=2008; citation_pages=717-719; citation_doi=10.1136/ard.2007.082925; citation_id=CR10
citation_journal_title=Rheumatology (Oxford); citation_title=Switching anti-TNFα therapy in ankylosing spondylitis; citation_author=DJ Pradeep, AC Keat, K Gaffney; citation_volume=47; citation_publication_date=2008; citation_pages=1726-1727; citation_doi=10.1093/rheumatology/ken334; citation_id=CR11
citation_journal_title=Scand J Rheumatol; citation_title=Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry of Karolinsk University Hospital; citation_author=MC Wick, S Lindblad, J Bratt; citation_volume=34; citation_publication_date=2005; citation_pages=353-358; citation_doi=10.1080/03009740510026887; citation_id=CR12
citation_journal_title=Clin Exp Rheum; citation_title=The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis; citation_author=G Cohen, N Courvoisier, JD Cohen; citation_volume=23; citation_publication_date=2005; citation_pages=795-800; citation_id=CR13
citation_journal_title=Rheumatology; citation_title=Lack of efficacy of a third tumor necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibody; citation_author=E Solau-Gervais, N Laxenaire, B Cortet; citation_volume=45; citation_publication_date=2006; citation_pages=1121-1124; citation_doi=10.1093/rheumatology/kel054; citation_id=CR14
citation_journal_title=Ann Rheum Dis; citation_title=Efficacy and safety of switching from infliximab to adalimumab: a comparison controlled study; citation_author=SN Nikas, PV Voulgari, Y Alamanos; citation_volume=65; citation_publication_date=2006; citation_pages=257-260; citation_doi=10.1136/ard.2005.039099; citation_id=CR15
citation_journal_title=Arthritis Rheum; citation_title=Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study; citation_author=KL Hyrich, M Lunt, KD Watson; citation_volume=56; citation_publication_date=2007; citation_pages=13-20; citation_doi=10.1002/art.22331; citation_id=CR16
citation_journal_title=Ann Rheum Dis; citation_title=Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?; citation_author=E Hjardem, M Ostergaard, J Podenphant; citation_volume=66; citation_publication_date=2007; citation_pages=1185-1189; citation_doi=10.1136/ard.2006.054742; citation_id=CR17
citation_journal_title=Ann Rheum Dis; citation_title=Etanercept maintaines the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects; citation_author=F Iannone, F Trotta, C Montecucco; citation_volume=66; citation_publication_date=2007; citation_pages=249-252; citation_doi=10.1136/ard.2006.058776; citation_id=CR18
citation_journal_title=Ann Rheum Dis; citation_title=Open-label pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study; citation_author=DE Furst, N Gaylis, V Bray; citation_volume=66; citation_publication_date=2007; citation_pages=893-899; citation_doi=10.1136/ard.2006.068304; citation_id=CR19
citation_journal_title=Rheumatology (Oxford); citation_title=Effects of switching between anti-TNFα therapies on HAQ response in patients who do not respond to their first anti-TNFα drug; citation_author=KL Hyrich, M Lunt, WG Dixon; citation_volume=47; citation_publication_date=2008; citation_pages=1000-1005; citation_doi=10.1093/rheumatology/ken127; citation_id=CR20
citation_journal_title=Arthr Rheum; citation_title=B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor α agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor α agents; citation_author=A Finckh, A Ciurea, L Brulhart; citation_volume=56; citation_publication_date=2007; citation_pages=1417-1423; citation_doi=10.1002/art.22520; citation_id=CR21
citation_journal_title=Drugs; citation_title=Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFα antagonists; citation_author=JR Lutt, A Deodhar; citation_volume=68; citation_publication_date=2008; citation_pages=591-606; citation_doi=10.2165/00003495-200868050-00003; citation_id=CR22